title: Reply to K.I. Pritchard.
authors.affiliation: Leiden University Medical Center, Leiden, the Netherlands.
authors.forename: Duveken B Y
authors.initials: DB
authors.lastname: Fontein
authors.forename: Cornelis J H
authors.initials: CJ
authors.lastname: van de Velde
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005831:Genital Diseases, Female / Q000139:chemically induced; D006801:Humans; D053208:Kaplan-Meier Estimate; D009140:Musculoskeletal Diseases / Q000139:chemically induced; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D016016:Proportional Hazards Models; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014666:Vasomotor System / Q000187:drug effects / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen